Dr. Brufsky on Biosimilars Being Explored in Oncology

Adam M. Brufsky, MD, PhD
Published: Wednesday, Mar 28, 2018



Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses biosimilars currently being explored in cancer.

There is a biosimilar for bevacizumab (Avastin) in breast cancer, there is a biosimilar for rituximab (Rituxan) for lymphoma, and there is a biosimilar for a pegylated G-CSF analog (pegfilgrastim) that is under review. According to Brufsky, those are the important biosimilars coming down the pipeline soon, but there are a lot of other compounds that people are talking about.

With trastuzumab (Herceptin), investigators are trying different formulations. Subcutaneous trastuzumab has the advantage of being able to be given at home with an injector. That kind of formulation is very popular outside of the United States, explains Brufsky.
 


Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses biosimilars currently being explored in cancer.

There is a biosimilar for bevacizumab (Avastin) in breast cancer, there is a biosimilar for rituximab (Rituxan) for lymphoma, and there is a biosimilar for a pegylated G-CSF analog (pegfilgrastim) that is under review. According to Brufsky, those are the important biosimilars coming down the pipeline soon, but there are a lot of other compounds that people are talking about.

With trastuzumab (Herceptin), investigators are trying different formulations. Subcutaneous trastuzumab has the advantage of being able to be given at home with an injector. That kind of formulation is very popular outside of the United States, explains Brufsky.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Publication Bottom Border
Border Publication
x